Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA a2,3 receptor positive allosteric modulator Deepens Axsome's broad and innovative neuroscience portfolio with a synergis ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback